lapachone
Small moleculeexperimental
Clinical trial activity
14 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00075933)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Carcinoma · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Cholangitis · Phase 2
- Cholangitis, Sclerosing · Phase 2
- Head and Neck Neoplasms · Phase 2
- Lymphoma · Phase 1
- Metabolic Syndrome · Phase 1
- Neoplasms · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2
- Obesity · Phase 1
- Pancreatic Neoplasms · Phase 2
Mechanism of action
- Topoisomerase I/IIINHIBITOR
Topoisomerase I/II inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O- Mol. weight
- 242.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL15192 ↗
Also known as
- 3,4-dihydro-2,2-dimethyl-2h-naphtho(1,2-b)pyran-5,6-dione
- arq 501
- arq 501
- arq 501
- beta-lapachone
- lapachone
- mb12066
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06975150 | Phase 2 | Aug 18, 2025 | CuromeBiosciences |
| NCT05866809 | Phase 2 | Oct 28, 2021 | CuromeBiosciences, University of Ulsan |
| NCT03575078 | Phase 1 | Oct 23, 2018 | The University of Texas, Dallas |
| NCT02338856 | Phase 1 | Jan 1, 2015 | KT&G Corporation |
| NCT02029586 | Phase 2 | Jan 1, 2013 | KT&G Corporation |
| NCT01444677 | Phase 1 | Apr 1, 2011 | KT&G Corporation, Seoul National University |
| NCT01285388 | Phase 1 | Jul 1, 2010 | KT&G Corporation, Seoul National University |
| NCT00524524 | Phase 1 | Aug 1, 2007 | ArQule, Harvard University |
| NCT00622063 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2006 | ArQule, Mary Crowley Cancer Center |
| NCT00358930 | Phase 2 | Jul 1, 2006 | ArQule |
| NCT00310518 | Phase 2 | Feb 1, 2006 | ArQule |
| NCT00102700 | Phase 2 | Jan 1, 2005 | ArQule |
| NCT00099190 | Phase 1 | Dec 1, 2004 | ArQule, Mary Crowley Cancer Center |
| NCT00075933 | Phase 1 | Sep 1, 2003 | ArQule, Harvard University, Mary Crowley Cancer Center |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ArQule | For profit | 7 | 7 | 2 | 2003 |
| KT&G Corporation | For profit | 4 | 4 | 2 | 2010 |
| Mary Crowley Cancer Center | Academic/Hospital | 3 | 0 | 2 | 2003 |
| CuromeBiosciences | For profit | 2 | 2 | 1 | 2021 |
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2003 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1